Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer

In treatment-naive, EGFR-mutant oligometastatic NSCLC, adding upfront SBRT to lazertinib is a viable therapeutic option with a manageable safety profile.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-01-27
DOI
https://doi.org/10.1016/j.esmoop.2025.106057
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer

M.H. Hong, S. Yoon, S.Y. Song, S. Jo et al.
ESMO Open
Lung Cancer Treatments and Mutations
article

Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer

M.H. Hong, S. Yoon, S.Y. Song, S. Jo, S.S. Lee, H.J. Kim, H.K. Ahn, S.J. Choi, K.H. Kim, J.B. Lee, H. Park, S.M. Lim, B.C. Cho, H.I. Yoon
article en

Abstract

In treatment-naive, EGFR-mutant oligometastatic NSCLC, adding upfront SBRT to lazertinib is a viable therapeutic option with a manageable safety profile.

ESMO OpenVol. 11(2)
Ulsan College (KR), Yonsei University (KR), Severance Hospital (KR), Asan Medical Center (KR), Samsung Medical Center (KR), University of Ulsan (KR), Gachon University Gil Medical Center (KR), Inje University Haeundae Paik Hospital (KR), Yonsei University Health System (KR)
Good health and well-being
Openalex Percentile: Top 78%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer — M.H. Hong, S. Yoon, et al. · ESMO Open (2026) | TGRS Research Map | TGRS